Create is expected to achieve double-digit year-over-year revenue growth in Q1, excluding nonstrategic revenue, with a ...
BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) ...